欧洲专利局给予Gentral Biosciences的SIRT6基因疗法临时保护,这是最后批准的关键一步。 The European Patent Office granted provisional protection for Genflow Biosciences' SIRT6 gene therapy, a key step toward final approval.

2025年10月20日欧洲专利局宣布,欧洲专利局在其SIRT6基因疗法应用中承认申请专利权,这标志着它最终获得赠款道路上的一个重要里程碑。 Genflow Biosciences PLC announced on October 20, 2025, that the European Patent Office has recognized the patentability of claims in its SIRT6 gene therapy application, marking a key milestone in its path to final grant. 该专利于10月15日公布, 给予EPO成员国临时保护, 并强化该公司对铅疗法(GF-1002)的知识产权。 The patent, published on October 15, grants provisional protection across EPO member states and strengthens the company’s intellectual property for its lead therapy, GF-1002, which is being tested in a 12-month proof-of-concept trial in aged dogs starting March 2025. 还计划开展其他以MASH为目标的临床方案。 Additional clinical programs targeting MASH are planned. 发展支持了Genflow的长期战略以及建立伙伴关系和筹资的潜力。 The development supports Genflow’s long-term strategy and potential for partnerships and funding.